Stocks
AKINA THERAPEUTICS INCORPORATEDAKNA
HealthcareBiotechnology
A clinical-stage biopharmaceutical company focused on developing therapies for rare diseases, with a pipeline centered on enzyme replacement and gene therapy approaches. Investors track AKNA for its lead candidate targeting a specific lysosomal storage disorder and its potential to address unmet medical needs in niche patient populations.
Congressional Interest in AKINA THERAPEUTICS INCORPORATED (AKNA)
1 member of Congress has disclosed 1 trade in AKINA THERAPEUTICS INCORPORATED (AKNA), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading AKNA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-06-28 | JAMES B. RENACCI | buy | $1K-$15K |